Excited and proud to see the main work from my PhD and postdoc on the development of "GLP-1 directed NMDA receptor antagonism for obesity treatment" out in @Nature today!
https://t.co/LLDn8oVbph
1/7 🧵
📚In our Review, we synthesize the rapidly expanding knowledge across the field from the clinical breakthroughs that have reshaped obesity treatment, to the molecular mechanisms behind the next generation of obesity therapies now moving through the pipeline.
The evolving landscape of obesity pharmacotherapy
https://t.co/g87Q1eGjgT
https://t.co/WBz2UaPWU2
This new Review covers the evolution of obesity therapy from GLP1s to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting
The evolving landscape of obesity pharmacotherapy
https://t.co/g87Q1eGjgT
https://t.co/WBz2UaPWU2
This new Review covers the evolution of obesity therapy from GLP1s to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting
1/8
🧠 New review from the lab in @CellCellPress: Brain Control of Energy Homeostasis
We explore how central nervous system circuits regulate energy balance, and how this informs the development of next-generation obesity pharmacotherapies.
🔗 https://t.co/9OaWTO2cKy
Thrilled to have contributed to this snapshot article on "Brain-Targeting Anti-Obesity Medications" appearing today in @Cell_Metabolism on #WorldObesityDay.
1/4 New paper out in @MolMetab in which we show that calorie restriction before starting treatment with semaglutide or tirzepatide pushes maximum achievable weight loss by ~8% https://t.co/sVjfY5jdnD
A few months back, we published a study in @ScienceAdvances demonstrating the potential of targeting postsynaptic glutamate receptor scaffolding proteins, such as PSD-95, for sustained weight loss. Headed by @nicolefadahunsi, @OdgaardJonas and @Met_Sop https://t.co/lJtsrirdTP
Big day for the lab as our latest paper is out in Nature Chemical Biology @nchembio on identifying the oxybipins as new OSBP inhibitors, as well as their mechanism of action and therapeutic applications! https://t.co/oP2HIcDiUT 1/n
@alexshauser@NatMetabolism Congratulations on publishing this amazing piece of work! 🥳Very important for understanding the complexities of GIP-based anti-obesity medicines.
Excited and proud to see the main work from my PhD and postdoc on the development of "GLP-1 directed NMDA receptor antagonism for obesity treatment" out in @Nature today!
https://t.co/LLDn8oVbph
1/7 🧵
4/7 To safely harvest the appetite-modulating effects of NMDAR antagonism, we engineered a first-in-class dual-acting compound that chemically combines GLP-1R agonism and NMDAR antagonism in a single Trojan horse like molecule.
6/7 Check out the informative thread by @ClemmensenC. It has been absolutely amazing working on this piece together, and I am excited to continue working on the next-generation of compounds in @OusiaPharma together with @BueKlein with support from @BioCPH and @Innofond .